YH006
YH006 is a potentially first-in-class CTLA-4 x OX40 bispecific antibody for the treatment of solid tumors. YH006 simultaneously binds both CTLA-4 and OX40 to enhance the antineoplastic activity while at the same time decreasing the adverse effects of immunotherapy. It is currently at CMC stage.
+86-010-56967680
Copyright © 2021 Biocytogen. All Rights Reserved
Powered by Fractal-technology